ProMIS Neurosciences raises $30.3M in PIPE financing with warrants for up to $92.4M more

ProMIS Neurosciences Inc.

Gross proceeds of $30.3M from sale of 9,757,669 common units at $2.15/unit and 4,371,027 pre-funded units at $2.14/unit.
Each unit includes one common share (or pre-funded warrant) and Tranche A, B, and C warrants with exercise prices of $2.02, $2.02, and $2.50, respectively.
Tranche A/B warrants subject to shareholder approval and expire upon 6-month or 12-month PMN310 data announcement; Tranche C expires July 31, 2029.
Proceeds to advance clinical development of PMN310, an antibody for Alzheimer's disease, plus working capital and general expenses.
All outstanding Series 2 Preferred Shares automatically convert into 1,166,667 common shares upon closing of this offering.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.